• 1
    Bosetti C, Rosato V, Gallus S, et al. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 2012;23:140315.
  • 2
    Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012;13:51827.
  • 3
    Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012;379:160212.
  • 4
    Jacobs EJ, Newton CC, Gapstur SM, et al. Daily aspirin use and cancer mortality in a large US cohort. J Natl Cancer Inst 2012;104:120817.
  • 5
    van Herk-Sukel MP, van de Poll-Franse LV, Lemmens VE, et al. New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO record linkage system. Eur J Cancer 2010;46:395404.
  • 6
    Eindhoven Cancer Registry. Avalable at: <>. (Accessed: 27 April 2013).
  • 7
    Schouten LJ, Hoppener P, van den Brandt PA, et al. Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol 1993;22:36976.
  • 8
    Dutch federation of Biomedical Scientific Societies, Code of conduct for health research, 2004.
  • 9
    PHARMO institute for drug outcome research. Available at: <>. (Accessed: 15 May 2013).
  • 10
    Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:91520.
  • 11
    Ruiter R, Visser LE, van Herk-Sukel MP, et al. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 2012;55:5162.
  • 12
    Joosse A, Koomen ER, Casparie MK, et al. Non-steroidal anti-inflammatory drugs and melanoma risk: large Dutch population-based case-control study. J Invest Dermatol 2009;129:26207.
  • 13
    Stricker BH, Stijnen T. Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies. Eur J Epidemiol 2010;25:24551.
  • 14
    Chan AT, Giovannucci EL, Meyerhardt JA, et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005;294:91423.
  • 15
    Walter RB, Milano F, Brasky TM, et al. Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective vitamins and lifestyle (VITAL) study. J Clin Oncol 2011;29:242431.
  • 16
    Curiel-Lewandrowski C, Nijsten T, Gomez ML, et al. Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol 2011;131:14608.
  • 17
    Jeter JM, Han J, Martinez ME, et al. Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses' health study. Cancer Causes Control 2012;23:145161.
  • 18
    Johannesdottir SA, Chang ET, Mehnert F, et al. Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer 2012;118:476876.
  • 19
    Nunes AP, Lapane KL, Weinstock MA, et al. Association between non-steroidal anti-inflammatory drugs and keratinocyte carcinomas of the skin among participants in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Pharmacoepidemiol Drug Saf 2011;20:9229.
  • 20
    Burn J, Bishop DT, Mecklin JP, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 2008;359:256778.
  • 21
    Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011;378:20817.
  • 22
    Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:4755.
  • 23
    Cook NR, Lee IM, Zhang SM, et al. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 2013;159:7785.
  • 24
    Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012;172:20916.
  • 25
    Antithrombothic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:184960.
  • 26 Available at: <>. (Accessed: 21 May 2013).
  • 27
    Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367:1596606.
  • 28
    Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008;167:4929.
  • 29
    Beyersmann J, Gastmeier P, Wolkewitz M, et al. An easy mathematical proof showed that time-dependent bias inevitably leads to biased effect estimation. J Clin Epidemiol 2008;61:121621.
  • 30
    Renehan AG. Insulin analogues and cancer risk: the emergence of second-generation studies. Diabetologia 2012;55:79.
  • 31
    Yood MU, Campbell UB, Rothman KJ, et al. Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiol Drug Saf 2007;16:9618.